Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10929)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Aug 15, 2015 (publication date) through Sep 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Guillebon E, Roussille P, Frouin E, Tougeron D. Anti program death-1/anti program death-ligand 1 in digestive cancers. World J Gastrointest Oncol 2015; 7(8): 95-101 [PMID: 26306141 DOI: 10.4251/wjgo.v7.i8.95] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v7/i8/95.htm |
| Number | Citing Articles |
| 1 |
Guoli Chen, Zhaohai Yang, James R. Eshleman, George J. Netto, Ming-Tseh Lin. Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. BioMed Research International 2016; 2016: 1 doi: 10.1155/2016/9850690
|
| 2 |
Carrick Burns, Shelby Kubicki, Quoc-Bao Nguyen, Nader Aboul-Fettouh, Kelly M. Wilmas, Olivia M. Chen, Hung Quoc Doan, Sirunya Silapunt, Michael R. Migden. Advances in Cutaneous Squamous Cell Carcinoma Management. Cancers 2022; 14(15): 3653 doi: 10.3390/cancers14153653
|
| 3 |
Angela Damato, Martina Rotolo, Francesco Caputo, Eleonora Borghi, Francesco Iachetta, Carmine Pinto. New Potential Immune Biomarkers in the Era of Precision Medicine: Lights and Shadows in Colorectal Cancer. Life 2022; 12(8): 1137 doi: 10.3390/life12081137
|
| 4 |
André F. Oliveira, Luís Bretes, Irene Furtado. Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer. Frontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.00396
|
| 5 |
Julien Taïeb, Thierry André, Farid El Hajbi, Emilie Barbier, Clémence Toullec, Stefano Kim, Olivier Bouche, Frederic Di Fiore, Marion Chauvenet, Hervé Perrier, Ludovic Evesque, Pierre Laurent-Puig, Jean-François Emile, Jérémie Bez, Côme Lepage, David Tougeron. Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. Digestive and Liver Disease 2021; 53(3): 318 doi: 10.1016/j.dld.2020.11.031
|
| 6 |
Zoran Gatalica, Semir Vranic, Joanne Xiu, Jeffrey Swensen, Sandeep Reddy. High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine. Familial Cancer 2016; 15(3): 405 doi: 10.1007/s10689-016-9884-6
|
| 7 |
Christine Böger, Hans-Michael Behrens, Micaela Mathiak, Sandra Krüger, Holger Kalthoff, Christoph Röcken. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget 2016; 7(17): 24269 doi: 10.18632/oncotarget.8169
|
| 8 |
Leon Chen, Alexander B. Aria, Sirunya Silapunt, Michael R. Migden. Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin Cancer. Dermatologic Surgery 2019; 45(1): 1 doi: 10.1097/DSS.0000000000001601
|
| 9 |
Paula Baraúna Assumpção, Erika Couto Canelas, Aline Cruz Ramos, Ana Anaissi, João Felipe Acioli, Geraldo Ishak, Sidney Santos, Samia Demachki, Paulo Assumpção. Lymph nodes may be a source for immunetherapy in gastric cancer. Oncotarget 2020; 11(19): 1729 doi: 10.18632/oncotarget.27578
|
| 10 |
Minyu Wang, Rita A Busuttil, Sharon Pattison, Paul J Neeson, Alex Boussioutas. Immunological battlefield in gastric cancer and role of immunotherapies. World Journal of Gastroenterology 2016; 22(28): 6373-6384 doi: 10.3748/wjg.v22.i28.6373
|
| 11 |
Huan Bin Wang, Han Yao, Chu Shu Li, Lun Xi Liang, Yao Zhang, Ying Xuan Chen, Jing‐Yuan Fang, Jie Xu. Rise of PD‐L1 expression during metastasis of colorectal cancer: Implications for immunotherapy. Journal of Digestive Diseases 2017; 18(10): 574 doi: 10.1111/1751-2980.12538
|
| 12 |
Esmeralda Celia Marginean, Barbara Melosky. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II—The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer. Archives of Pathology & Laboratory Medicine 2018; 142(1): 26 doi: 10.5858/arpa.2017-0041-RA
|
| 13 |
Lingyu Li, Wei Li, Chang Wang, Xu Yan, Yizhuo Wang, Chao Niu, Xiaoying Zhang, Min Li, Huimin Tian, Cheng Yao, Haofan Jin, Fujun Han, Dongsheng Xu, Wei Han, Dan Li, Jiuwei Cui. Adoptive transfer of natural killer cells in combination with chemotherapy improves outcomes of patients with locally advanced colon carcinoma. Cytotherapy 2018; 20(1): 134 doi: 10.1016/j.jcyt.2017.09.009
|
| 14 |
Hamzah Abu-Sbeih, Yinghong Wang. Immunotherapy. Advances in Experimental Medicine and Biology 2020; 1244: 247 doi: 10.1007/978-3-030-41008-7_12
|
| 15 |
Ye Hong, Zhen-Yu Ding. PD-1 Inhibitors in the Advanced Esophageal Cancer. Frontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.01418
|
| 16 |
|
| 17 |
Surinder M. Soond, Andrey A. Zamyatnin. Helicobacter pylori and gastric cancer: a lysosomal protease perspective. Gastric Cancer 2022; 25(2): 306 doi: 10.1007/s10120-021-01272-8
|
| 18 |
L Liu, Y Wang, R Bai, K Yang, Z Tian. MiR-186 inhibited aerobic glycolysis in gastric cancer via HIF-1α regulation. Oncogenesis 2016; 5(5): e224 doi: 10.1038/oncsis.2016.35
|
| 19 |
James W.T. Toh, Paul de Souza, Stephanie H. Lim, Puneet Singh, Wei Chua, Weng Ng, Kevin J. Spring. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. Clinical Colorectal Cancer 2016; 15(4): 285 doi: 10.1016/j.clcc.2016.07.007
|
| 20 |
Animesh Saurabh, Vandana Raphael, Biswajit Dey, Caleb Harris, Vikas Jagtap, Umesh Das. Expression of PDL1 and Her2neu in Gastric and Gastroesophageal Junction Adenocarcinoma. Indian Journal of Surgical Oncology 2021; 12(S1): 144 doi: 10.1007/s13193-020-01245-w
|
| 21 |
Zheyu Song, Yuanyu Wu, Jiebing Yang, Dingquan Yang, Xuedong Fang. Progress in the treatment of advanced gastric cancer. Tumor Biology 2017; 39(7): 101042831771462 doi: 10.1177/1010428317714626
|
| 22 |
Junhun Cho, Kyoung-Mee Kim, Hee Cheol Kim, Woo Yong Lee, Won ki Kang, Young Suk Park, Sang Yun Ha. The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma. Pathology - Research and Practice 2019; 215(1): 171 doi: 10.1016/j.prp.2018.10.024
|
| 23 |
Naoki Takahashi, Satoru Iwasa, Yusuke Sasaki, Hirokazu Shoji, Yoshitaka Honma, Atsuo Takashima, Natsuko Tsuda Okita, Ken Kato, Tetsuya Hamaguchi, Yasuhide Yamada. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. Journal of Cancer Research and Clinical Oncology 2016; 142(8): 1727 doi: 10.1007/s00432-016-2184-6
|
| 24 |
Hye Jung Cho, Woo Ram Kim, Joo-Hang Kim, Duk Hwan Kim, Dae Jung Kim, Haeyoun Kang. Colonic Perforation After Treatment With Nivolumab in Esophageal Cancer: A Case Report. Annals of Coloproctology 2021; 37(Suppl 1): S39 doi: 10.3393/ac.2020.00213.0030
|
| 25 |
Xiaofang Xing, Jianping Guo, Guangyu Ding, Bo Li, Bin Dong, Qin Feng, Shen Li, Jian Zhang, Xiaomin Ying, Xiaojing Cheng, Ting Guo, Hong Du, Ying Hu, Tao Zhou, Xiaohong Wang, Lin Li, Qingda Li, Meng Xie, Liting Li, Xiangyu Gao, Fei Shan, Ziyu Li, Shuqin Jia, Xianzi Wen, Jiping Wang, Jiafu Ji. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. OncoImmunology 2018; 7(3): e1356144 doi: 10.1080/2162402X.2017.1356144
|
| 26 |
David J. Birnbaum, François Bertucci, Pascal Finetti, Daniel Birnbaum, Emilie Mamessier. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2018; 1869(2): 248 doi: 10.1016/j.bbcan.2018.02.001
|
| 27 |
Ruiqi Liu, Ke Peng, Yiyi Yu, Li Liang, Xiaojing Xu, Wei Li, Shan Yu, Tianshu Liu. Prognostic Value of Immunoscore and PD-L1 Expression in Metastatic Colorectal Cancer Patients with Different RAS Status after Palliative Operation. BioMed Research International 2018; 2018: 1 doi: 10.1155/2018/5920608
|
| 28 |
Yun Tian, Hamzah Abu-Sbeih, Yinghong Wang. Immunotherapy. Advances in Experimental Medicine and Biology 2018; 995: 151 doi: 10.1007/978-3-030-02505-2_7
|
| 29 |
Apostolos Zaravinos, Constantinos Roufas, Majdi Nagara, Beatriz de Lucas Moreno, Maria Oblovatskaya, Christodoulos Efstathiades, Christos Dimopoulos, Georgios D. Ayiomamitis. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer. Journal of Experimental & Clinical Cancer Research 2019; 38(1) doi: 10.1186/s13046-019-1372-z
|
| 30 |
Camille Evrard, Gaëlle Tachon, Violaine Randrian, Lucie Karayan-Tapon, David Tougeron. Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer. Cancers 2019; 11(10): 1567 doi: 10.3390/cancers11101567
|
| 31 |
Giuseppe Ercolano, Maryline Falquet, Giulia Vanoni, Sara Trabanelli, Camilla Jandus. ILC2s: New Actors in Tumor Immunity. Frontiers in Immunology 2019; 10 doi: 10.3389/fimmu.2019.02801
|
| 32 |
Sheik Emambux, Gaelle Tachon, Audelaure Junca, David Tougeron. Results and challenges of immune checkpoint inhibitors in colorectal cancer. Expert Opinion on Biological Therapy 2018; 18(5): 561 doi: 10.1080/14712598.2018.1445222
|
| 33 |
Xukai Luo, Yini Shen, Wu Huang, Yiting Bao, Jiahang Mo, Liangqing Yao, Lei Yuan. Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer. Cancer Control 2023; 30: 107327482311597 doi: 10.1177/10732748231159706
|
| 34 |
Kyung-Ju Kim, Han Kwang Yang, Woo Ho Kim, Gyeong Hoon Kang. Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers. Oncotarget 2017; 8(35): 58887 doi: 10.18632/oncotarget.19439
|
| 35 |
Kelly M Wilmas, Quoc-Bao Nguyen, Jigar Patel, Sirunya Silapunt, Michael R Migden. Treatment of Advanced Cutaneous Squamous Cell Carcinoma: A Mohs Surgery and Dermatologic Oncology Perspective. Future Oncology 2021; 17(35): 4971 doi: 10.2217/fon-2021-0901
|
| 36 |
Basile Tessier-Cloutier, Steve E. Kalloger, Mohammad Al-Kandari, Katy Milne, Dongxia Gao, Brad H. Nelson, Daniel J. Renouf, Brandon S. Sheffield, David F. Schaeffer. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. BMC Cancer 2017; 17(1) doi: 10.1186/s12885-017-3634-5
|
| 37 |
Qingfang Zhao, Liang Cao, Lulu Guan, Liangyu Bie, Saiqi Wang, Bojian Xie, Xiaobing Chen, Xiaokun Shen, Feiling Cao. Immunotherapy for gastric cancer: dilemmas and prospect. Briefings in Functional Genomics 2019; 18(2): 107 doi: 10.1093/bfgp/ely019
|
| 38 |
Yajie Zhang, Jingwei Tan, Lu Zhou, Xiaoqing Shan, Jianling Liu, Yong Ma. Synthesis and Application of AS1411-Functionalized Gold Nanoparticles for Targeted Therapy of Gastric Cancer. ACS Omega 2020; 5(48): 31227 doi: 10.1021/acsomega.0c04605
|
| 39 |
Simon Pernot, Toulsie Ramtohul, Julien Taieb. Checkpoint inhibitors and gastrointestinal immune-related adverse events. Current Opinion in Oncology 2016; 28(4): 264 doi: 10.1097/CCO.0000000000000292
|
| 40 |
Shenying Jin, Bo Xu, Lixia Yu, Yao Fu, Hongyan Wu, Xiangshan Fan, Jia Wei, Baorui Liu. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy. Oncotarget 2017; 8(24): 38850 doi: 10.18632/oncotarget.16407
|
| 41 |
星辰 周. New Progress of Immunotherapy in Gastric Cancer. Advances in Clinical Medicine 2023; 13(03): 4904 doi: 10.12677/ACM.2023.133700
|